PD-1/PD-L1 governed cross-talk of exhausted CD8+ T and memory B cells in systemic lupus erythematosus

Kaiwen Wang,Jiangfeng Zhao,Xuemei Feng,Shuangjun He,Jia Li,Fangfang Sun,Zhangling Xu,Haiting Yang,Jiaer Ye,Liou Cao,Shuang Ye

DOI: https://doi.org/10.1136/rmdopen-2023-003503

2024-01-18

RMD Open

Abstract:Background Indeterminate readout of the quantitative interferon- release test (QFT) for Mycobacterium tuberculosis screening is a specific laboratory finding for systemic lupus erythematosus (SLE), which may be due to T-cell exhaustion and abnormal programmed death receptor 1 (PD-1)/programmed death-ligand 1 (PD-L1) signalling. Methods We enrolled 104 patients with SLE and 225 with other rheumatic musculoskeletal diseases (RMDs) who presented to the outpatient clinic between 2020 and 2023. Twenty healthy donors served as the controls. The QFT was performed in all participants, and those with indeterminate results were compared among the groups. Immunophenotyping and functional assays were performed using blood mononuclear cells. Interferon (IFN)- was detected in vitro and ex vivo in patients with SLE with indeterminate or negative QFT results, before or after rituximab therapy. Results 104 patients with SLE had a significantly higher rate of indeterminate QFT results was significantly higher (17.31%) than that of 225 patients with RMD (3.56%). Patients with SLE with indeterminate QFT had more active disease (SLEDAI-2K, mean 10.94 vs 4.02, p<0.0001), including a higher incidence of active nephritis (55.56% vs 29.07%). Indeterminate QFT in SLE is mainly caused by an insufficient IFN- response in CD8+T cells with exhausted immunophenotypes. The abnormal interaction between exhausted PD-1 high CD8 + T cells and activated PD-L1 low memory B cells in SLE can be reversed with a PD-1 agonist or increased PD-L1 expression. Rituximab treatment indirectly reversed this IFN- response. Conclusion The PD-1/PD-L1 signalling pathway, which governs the crosstalk between exhausted CD8 + T cells and activated memory B cells, is a mechanistic explanation for insufficient interferon- response in patients with SLE.

rheumatology

What problem does this paper attempt to address?

T - cell immunoglobulin - 3 (TIM3), B - and T - lymphocyte attenuator (BTLA), and killer - cell lectin - like receptor G1 (KLRG1)). The results showed that in patients with IIR - SLE, the expression of these exhaustion markers on CD8+ T cells was significantly increased (Figure 2A, Supplementary Figure 4). In addition, compared with the SLE control group, the proportion of high - expression PD - 1 in CD8+ T cells was higher in patients with IIR - SLE (Figure 2B), indicating that CD8+ T - cell exhaustion may be the main cause of IIR.

To further verify this hypothesis, the researchers used PD - 1 agonists or increased PD - L1 expression on memory B cells to observe the effect on CD8+ T - cell function. The results showed that PD - 1 agonists could partially restore CD8+ T - cell function, manifested as an increase in IFN - γ production (Figure 2C). Similarly, over - expressing PD - L1 on memory B cells by genetic engineering could also significantly improve the IFN - γ production ability of CD8+ T cells (Figure 2D). These results support the role of the PD - 1/PD - L1 signaling pathway in regulating CD8+ T - cell exhaustion and indicate that this pathway can be used as a new target for treating SLE.

**Conclusion**:
This study revealed the mechanism of interaction between PD - 1/PD - L1 signaling pathway in regulating CD8+ T - cell exhaustion and activated memory B cells in systemic lupus erythematosus (SLE), explaining the reason for the insufficient interferon - γ response in SLE patients. This finding not only enhances the understanding of the immunopathological mechanism of SLE, but also may provide a theoretical basis for the development of new treatment methods.